Myotonic dystrophy (DM) is an autosomal dominant genetic disease caused by an unstable CTG repeat sequence in the 3' untranslated region of the myotonin protein kinase gene. The CTG repeat is present times in the normal population,whereas DM patients have CTG expansions of 50 to several thousand repeats. The age of onset of the disorder and the severity of the phenotype is roughly correlated with the size of the CTG expansion. We developed a molecular protocol for the diagnosis of DM based on an initial polymerase chain reaction screen to detect normal-sized alleles and small expansions, followed by an improved Southern protocolto detect larger expansions. Because of its highly variable expression, the diagnosis of DM may not be straightforward in many cases. Moreover, the late age of onset often makes genetic counseling difficult, since the affected individual may not be diagnosed until after having had children. Genetic anticipation, the occurrence of symptoms at progressively earlier ages in successive generations, has been observed in DM (1, 2). A severe congenital form occurs among offspring of affected mothers.
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The DM mutation was recently identified as an unstable CTG triplet repeat located in the 3' untranslated region of the myotonin protein kinase gene (3) (4) (5) (6) (7) (8) . This CTG repeat is polymorphic in the normal population, having a range of 5 to 30 repeats. In DM-affected patients, the repeat number expands from 50 to several thousand (3, 9). As in Fragile X syndrome, the copy number tends to increase in successive generations, accounting for the anticipation phenomenon (5, 6, 10-14), and the expanded repeats are often both meiotically and mitotically unstable (4, 15) . Recombinant DNA techniques are now being routinely used to confirm the diagnosis of DM in affected individuals (16) . The goal of this study was to develop a new molecular-based protocol for the diagnosis of DM. (pMDY1) fragment (3, 4) The original cDNA probe (pMDY1) included the CTG repeat region (4). Since these repeats are present elsewhere in the human genome, pMDY1 often produces high background when hybridized to the genomic DNA and thus requires blocking techniques.
Materials and Methods

We
Southern test for DM was performed on
The background may interfere with the detection of expanded alleles since the expanded alleles often appear as smears because of somatic instability of the mutation. To reduce the background and increase the sensitivity of the Southern test, we cut the BamHI fragment of pMDYI with SacII, releasing a 1-kb fragment located 5' of the CTG repeat. The new probe is highly specific for the myotonin gene. No new mutations have been described in DM, which is consistent with the linkage disequilibrium data. Thus, it is essential to identify on which side of the family the mutation is segregating to provide accurate risk assessment to all at-risk individuals in a family.
With our new Southern procedure, we are able to more accurately determine the size of the larger expansions in affected patients. Since the mutation is now on a 2.2-kb restriction fragment, rather than a 9.5-kb restriction fragment, it is possible to approximate the size 1-6, Il-i, and 11-2 (ages 32 to 54 ). There were reductions in the repeat size between 1-3 and 11-1 and between 1-5  and 11-2, which may have contributed to the absence of  phenotype in 11-1 and 11-2 If we detect a normal and a slightly expanded allele in the patient, the diagnosis is confirmed. Most importantly, since many of these patients with small expansions are asymptomatic, they can now be provided with accurate risk estimates and other family members can also be offered testing. If only one band is detected by PCR, we then perform our Southern analysis. As described in Fig. 4 , there are two possible outcomes. The first is that only one band will be present upon hybridization.
In this case the patient is ruled homozygous for the normal allele, and again other neuromuscular diseases should be considered. The second outcome is when an expanded allele is detected, thus confirming the diagnosis of DM. Since our recent development of this direct DNA analysis protocol for DM, we have been able to rule out a DM diagnosis in 41% of the cases with the PCR screen, thus directing the physicians towards other diagnoses. In 90% of the remaining cases we have confirmed the diagnosis of DM with our Southern test; the remaining 10% were shown to be homozygous for the normal PCR allele. Our protocol is both labor-and cost-effective, since we have reduced the number of Southern transfers being performed. Also, by eliminating the repeat from the probe and using a double digest, we have improved the quality of the Southern procedure.
